Drug Profile
Research programme: stem cell therapeutics - ImmuneRegen/Lisata Therapeutics
Latest Information Update: 19 Sep 2022
Price :
$50
*
At a glance
- Originator ImmuneRegen BioSciences; NeoStem
- Developer Lisata Therapeutics
- Class Antitoxins; Peptides; Stem cell therapies
- Mechanism of Action Cell replacements; Immunostimulants; Neurokinin 1 receptor agonists; Stem cell modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cardiovascular disorders; Musculoskeletal disorders; Neurological disorders
Most Recent Events
- 14 Sep 2022 Cend Therapeutics has merged with Caladrius Biosciences to form Lisata Therapeutics
- 16 Jul 2016 No recent reports of development identified for research development in Cardiovascular-disorders in USA
- 16 Jul 2016 No recent reports of development identified for research development in Musculoskeletal-disorders in USA